Skip to content
MGX·Nasdaq·US

Metagenomi

Metagenomi is an in vivo genome editing company that uses proprietary technologies to create curative genetic medicines for patients. It was founded on metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop novel gene editing tools. Its lead wholly-owned program, MGX-001, targets hemophilia A.

Source: SEC 10-K Mar 5, 2026

Thematic Position

MGX

Relationship Groups

Partners2
Licensing2
Competitors7

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

9 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariffarmed conflict
Increased U.S. trade tariffs and retaliatory tariffs and geopolitical conflicts affecting economic conditions
SEC 10-KMar 5, 2026

The full regulatory passage is part of the Pro plan.

2 more · Regulatory and geopolitical insights are part of the Pro plan.